KR102587934B1 - manufacturing method of attractive pill using Lepidium meyenii and silkworm - Google Patents
manufacturing method of attractive pill using Lepidium meyenii and silkworm Download PDFInfo
- Publication number
- KR102587934B1 KR102587934B1 KR1020220096581A KR20220096581A KR102587934B1 KR 102587934 B1 KR102587934 B1 KR 102587934B1 KR 1020220096581 A KR1020220096581 A KR 1020220096581A KR 20220096581 A KR20220096581 A KR 20220096581A KR 102587934 B1 KR102587934 B1 KR 102587934B1
- Authority
- KR
- South Korea
- Prior art keywords
- heating
- maca
- powder
- weight
- cinnamon
- Prior art date
Links
- 240000000759 Lepidium meyenii Species 0.000 title claims abstract description 44
- 235000000421 Lepidium meyenii Nutrition 0.000 title claims abstract description 44
- 235000012902 lepidium meyenii Nutrition 0.000 title claims abstract description 44
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 32
- 241000255789 Bombyx mori Species 0.000 title claims abstract description 28
- 239000006187 pill Substances 0.000 title claims abstract description 23
- 238000010438 heat treatment Methods 0.000 claims abstract description 59
- 239000000843 powder Substances 0.000 claims abstract description 43
- 240000006079 Schisandra chinensis Species 0.000 claims abstract description 33
- 235000008422 Schisandra chinensis Nutrition 0.000 claims abstract description 33
- 244000223760 Cinnamomum zeylanicum Species 0.000 claims abstract description 32
- 241000759833 Cornus officinalis Species 0.000 claims abstract description 32
- 235000017803 cinnamon Nutrition 0.000 claims abstract description 32
- 235000001287 Guettarda speciosa Nutrition 0.000 claims abstract description 23
- 244000061520 Angelica archangelica Species 0.000 claims abstract description 21
- 241000382353 Pupa Species 0.000 claims abstract description 17
- 239000012141 concentrate Substances 0.000 claims abstract description 17
- 239000002994 raw material Substances 0.000 claims abstract description 17
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims abstract description 13
- 229930064664 L-arginine Natural products 0.000 claims abstract description 13
- 235000014852 L-arginine Nutrition 0.000 claims abstract description 13
- 235000015872 dietary supplement Nutrition 0.000 claims abstract description 13
- 229960001109 policosanol Drugs 0.000 claims abstract description 13
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims abstract description 13
- 240000001810 Angelica gigas Species 0.000 claims abstract description 9
- 235000018865 Angelica gigas Nutrition 0.000 claims abstract description 9
- 238000001035 drying Methods 0.000 claims abstract description 8
- 238000002156 mixing Methods 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 8
- 240000001417 Vigna umbellata Species 0.000 claims description 6
- 235000011453 Vigna umbellata Nutrition 0.000 claims description 6
- 238000000227 grinding Methods 0.000 claims description 5
- 238000000465 moulding Methods 0.000 claims description 4
- 238000010298 pulverizing process Methods 0.000 claims description 3
- 235000019640 taste Nutrition 0.000 abstract description 40
- 230000000694 effects Effects 0.000 abstract description 24
- 206010012735 Diarrhoea Diseases 0.000 abstract description 13
- 230000017531 blood circulation Effects 0.000 abstract description 11
- 208000004998 Abdominal Pain Diseases 0.000 abstract description 10
- 230000036299 sexual function Effects 0.000 abstract description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 7
- 239000000047 product Substances 0.000 abstract description 4
- 206010063659 Aversion Diseases 0.000 abstract description 3
- 239000004480 active ingredient Substances 0.000 abstract description 3
- 230000001953 sensory effect Effects 0.000 description 24
- 230000000052 comparative effect Effects 0.000 description 22
- 238000012360 testing method Methods 0.000 description 20
- 235000008504 concentrate Nutrition 0.000 description 14
- 235000013305 food Nutrition 0.000 description 11
- 239000004615 ingredient Substances 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 208000007536 Thrombosis Diseases 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 102000009123 Fibrin Human genes 0.000 description 6
- 108010073385 Fibrin Proteins 0.000 description 6
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 6
- 235000019658 bitter taste Nutrition 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 229950003499 fibrin Drugs 0.000 description 6
- 235000019614 sour taste Nutrition 0.000 description 6
- 206010020751 Hypersensitivity Diseases 0.000 description 5
- 230000023555 blood coagulation Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 206010013911 Dysgeusia Diseases 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- 230000007815 allergy Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 108090000190 Thrombin Proteins 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- -1 p-methoxybenzyl Chemical group 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 229960004072 thrombin Drugs 0.000 description 3
- 206010000060 Abdominal distension Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 241000125175 Angelica Species 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 240000006766 Cornus mas Species 0.000 description 2
- 235000003363 Cornus mas Nutrition 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- HLXRWTJXGMHOFN-XJSNKYLASA-N Verbenalin Chemical compound O([C@@H]1OC=C([C@H]2C(=O)C[C@H](C)[C@H]21)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HLXRWTJXGMHOFN-XJSNKYLASA-N 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 239000000447 pesticide residue Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000009423 ventilation Methods 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 241000554155 Andes Species 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 241000208173 Apiaceae Species 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 102100023804 Coagulation factor VII Human genes 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000142975 Cornaceae Species 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 108010014172 Factor V Proteins 0.000 description 1
- 108010023321 Factor VII Proteins 0.000 description 1
- 108010080865 Factor XII Proteins 0.000 description 1
- 102000000429 Factor XII Human genes 0.000 description 1
- 108010071289 Factor XIII Proteins 0.000 description 1
- 102100029111 Fatty-acid amide hydrolase 1 Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- AMBQHHVBBHTQBF-UHFFFAOYSA-N Loganin Natural products C12C(C)C(O)CC2C(C(=O)OC)=COC1OC1OC(CO)C(O)C(O)C1O AMBQHHVBBHTQBF-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000218378 Magnolia Species 0.000 description 1
- 206010027304 Menopausal symptoms Diseases 0.000 description 1
- HXCGUCZXPFBNRD-QVYYAULWSA-N Nodakenin Natural products O(C(C)(C)[C@@H]1Oc2c(cc3c(OC(=O)C=C3)c2)C1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HXCGUCZXPFBNRD-QVYYAULWSA-N 0.000 description 1
- HXCGUCZXPFBNRD-DNLMCPORSA-N Nodakenin Chemical compound CC(C)([C@@H]1OC2=CC=3OC(=O)C=CC=3C=C2C1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HXCGUCZXPFBNRD-DNLMCPORSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- UFCGDBKFOKKVAC-DSASHONVSA-N Schisantherin A Chemical compound O([C@H]1C=2C=C(C(=C(OC)C=2C2=C(OC)C=3OCOC=3C=C2C[C@H](C)[C@@]1(O)C)OC)OC)C(=O)C1=CC=CC=C1 UFCGDBKFOKKVAC-DSASHONVSA-N 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- HLXRWTJXGMHOFN-UHFFFAOYSA-N Verbenalin Natural products C12C(C)CC(=O)C2C(C(=O)OC)=COC1OC1OC(CO)C(O)C(O)C1O HLXRWTJXGMHOFN-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 229940019700 blood coagulation factors Drugs 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000019784 crude fat Nutrition 0.000 description 1
- 235000021403 cultural food Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 229940012413 factor vii Drugs 0.000 description 1
- 229940012444 factor xiii Drugs 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 108010046094 fatty-acid amide hydrolase Proteins 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 229930186755 gomisin Natural products 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- AMBQHHVBBHTQBF-UOUCRYGSSA-N loganin Chemical compound O([C@@H]1OC=C([C@H]2C[C@H](O)[C@H](C)[C@H]21)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O AMBQHHVBBHTQBF-UOUCRYGSSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000012866 low blood pressure Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000006993 memory improvement Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- HXCGUCZXPFBNRD-UHFFFAOYSA-N nodakenine Natural products C1C2=CC=3C=CC(=O)OC=3C=C2OC1C(C)(C)OC1OC(CO)C(O)C(O)C1O HXCGUCZXPFBNRD-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 230000035946 sexual desire Effects 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/20—Agglomerating; Granulating; Tabletting
- A23P10/28—Tabletting; Making food bars by compression of a dry powdered mixture
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/01—Instant products; Powders; Flakes; Granules
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L35/00—Food or foodstuffs not provided for in groups A23L5/00 – A23L33/00; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/31—Foods, ingredients or supplements having a functional effect on health having an effect on comfort perception and well-being
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/326—Foods, ingredients or supplements having a functional effect on health having effect on cardiovascular health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/02—Acid
- A23V2250/06—Amino acid
- A23V2250/0606—Arginine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/10—Drying, dehydrating
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/24—Heat, thermal treatment
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/31—Mechanical treatment
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/38—Multiple-step
Abstract
본 발명은 마카, 누에 등을 이용한 건강보조식품용 환 및 제조 방법에 관한 것이다.
본 발명의 건강보조식품용 환은, 마카농축액 분말, 숫누에번데기 분말, 폴리코사놀 분말, L-아르지닌, 산수유, 참당귀, 오미자, 계피를 유효성분으로 하는 것을 특징으로 한다.
본 발명에 의해, 혈행 개선 및 성기능 개선에 효과가 있는 것으로 알려진 마카 및 누에번데기를 주 원료로 하여 환 형태로 제조하되, 물 없이 씹어서 취식할 때 맛과 향에 대한 거부감이 적고 체내 흡수가 원할히 이루어질 수 있게 된다. 더하여, 산수유, 참당귀, 오미자, 계피를 적절히 첨가하여 맛과 향에 대한 거부감이 최소화할 수 있게 된다. 또한, 산수유, 참당귀, 오미자, 계파를 습윤가열과 가열건조를 각각 온도와 시간을 달리하여 한정하여 진행함으로써 복통, 설사 등의 부작용이 최소화할 수 있게 된다.The present invention relates to pills and manufacturing methods for health supplements using maca, silkworm, etc.
The pill for health supplement of the present invention is characterized by containing maca concentrate powder, silkworm pupa powder, policosanol powder, L-arginine, Cornus officinalis, Angelica gigas, Schisandra chinensis, and cinnamon as active ingredients.
According to the present invention, maca and silkworm pupae, which are known to be effective in improving blood circulation and sexual function, are used as main raw materials to manufacture them in the form of pills, but when chewed and consumed without water, there is little resistance to taste and aroma and the product is easily absorbed into the body. It can be done. In addition, by appropriately adding Cornus officinalis, angelica root, Schisandra chinensis, and cinnamon, aversion to taste and aroma can be minimized. In addition, side effects such as abdominal pain and diarrhea can be minimized by limited wet heating and heat drying of Cornus officinalis, angelica root, Schisandra chinensis, and cinnamon at different temperatures and times.
Description
본 발명은 마카, 누에 등을 이용한 건강보조식품용 환 및 제조 방법에 관한 것이다.The present invention relates to pills and manufacturing methods for health supplements using maca, silkworm, etc.
인체 구성성분으로 혈액은 산소, 영양분, 노폐물의 운반 기능과 완충 작용, 체온 유지, 삼투압 조절 및 이온 평 형 유지, 수분 일정 유지, 액성 조절 작용, 혈압의 유지 및 조절, 생체 방어 등 다양한 중요 기능들을 가지고 있다. 정상적인 혈액 순환은 체내에서의 혈액 응고 반응계와 혈전 용해 반응계가 상호 보완적으로 조절되면서 혈액 순환을 용이하게 하며, 이들 중 혈액 응고 반응계의 기작은 혈관벽에 혈소판이 점착 및 응집하여 혈소판 혈전을 형성한 후, 혈액 응고계가 활성화되어 혈소판 응집괴를 중심으로 피브린 혈전이 형성되는 것으로 보고되 어 있다.As a component of the human body, blood performs a variety of important functions such as transportation of oxygen, nutrients, and waste, buffering, maintaining body temperature, regulating osmotic pressure and maintaining ionic balance, maintaining moisture content, regulating fluid volume, maintaining and regulating blood pressure, and biological defense. Have. Normal blood circulation facilitates blood circulation through complementary regulation of the blood coagulation response system and thrombolysis response system in the body. Among these, the mechanism of the blood coagulation response system is that platelets adhere and aggregate to the blood vessel wall to form a platelet thrombus. It has been reported that the blood coagulation system is activated and a fibrin thrombus is formed centered on platelet aggregates.
한편, 피브린 혈전의 생성은 수많은 혈액 응고 인자들의 여러 단계 반응을 거쳐 피브린 응고에 관여하는 트롬빈 이 활성화되어, 최종적으로 피브리노겐으로부터 피브린 단량체를 생성하게 하며, 피브린 단량체들은 칼슘에 의 해 중합되어, 혈소판과 내피세포에 결합하게 되며 XIII 인자에 의해 교차 결합된 피브린 폴리머를 형성하면서 영구적인 혈전을 생성하게 된다. 또한, 트롬빈은 혈소판, V 인자, VII 인자들을 활성화시켜 혈액 응고 반응을 촉진시키는 등 혈전 생성에 중추적 역할을 하게 된다. 따라서, 트롬빈의 활성 저해물질은 과다한 혈액 응고 이상으로 발생하는 다양한 혈전성 질환에 매우 유용한 예방 및 치료제로 사용될 수 있다. 한편, 내인성 혈전 생성 경로에는 XII 인자, XI 인자, IX 인자, X 인자의 순차적 활성화에 이은 프로트롬빈의 활성화가 최종적으로 트롬 빈을 활성화하는 것으로 알려져 혈액 응고 인자의 특이적 저해 역시 중요한 혈전성 질환 치료제의 개발 타겟이 되고 있다. 현재까지 혈전성 질환의 예방과 치료에 헤파린, 쿠마린, 아스피린, 유로키네이즈 등의 다양한 항응 고제, 항혈소판제, 혈전용해제 등이 사용되고 있으나, 이들은 가격이 매우 높을 뿐 아니라, 출혈성 부작용과 위 장 장해 및 과민 반응 등으로 그 사용이 한정되고 있는 실정이다.Meanwhile, the formation of a fibrin clot goes through several stages of reactions of numerous blood coagulation factors, and thrombin, which is involved in fibrin coagulation, is activated, ultimately producing fibrin monomers from fibrinogen. The fibrin monomers are polymerized by calcium, forming platelets and It binds to endothelial cells and forms a fibrin polymer cross-linked by factor XIII, creating a permanent blood clot. In addition, thrombin plays a central role in the formation of blood clots by activating platelets, factor V, and factor VII to promote blood coagulation. Therefore, substances that inhibit thrombin activity can be used as a very useful preventive and therapeutic agent for various thrombotic diseases caused by excessive blood coagulation abnormalities. Meanwhile, in the endogenous thrombus formation pathway, sequential activation of factor XII, factor It is becoming a development target. To date, various anticoagulants, antiplatelet agents, and thrombolytic agents such as heparin, coumarin, aspirin, and urokinase have been used to prevent and treat thrombotic diseases. However, these are not only very expensive, but also have hemorrhagic side effects, gastrointestinal disorders, and other side effects. Its use is limited due to hypersensitivity reactions.
마카(Lepidium meyenii)는 해발 4,000~4,500m의 페루 안데스 산맥에서 자생하는 십자화과 채소의 일종으로, maca-maca, maino, ayak willku 등의 다양한 이름으로 불려진다. 마카는 페루의 산삼이라 불릴 만큼 혹독한 자연환경에서 살아남는 강인한 생명력과 다양한 유용 생리 활성이 잘 알려진 식용 및 약용식물로, 식품으로 사용 되는 마카 지하부는 오랜 기간 동안의 섭취로 이미 안전성이 입증되어 있으며, 국내에서도 2005년부터 식품의약 품안전청으로부터 식품의 부원료로 사용이 허용되어 있다(권대중 외, 2009, 식품산업과 영양 14: 19~24). 마카 뿌리는 수분함량이 80% 이상이며, 건조 중량을 기준으로 할 때 조단백질 8.87~11.6%, 조지방 1.09~2.2%, 조회분 4.9~5.0%, 탄수화물 54.6~60.0%, 식이섬유 8.23~9.08%로 알려져 있다(Dini A 외, 1994. Food Chem 49: 347~349). 또한, oleic acid, linoleic acid, palmitic acid 등의 지방산과 철, 칼슘, 요오드, 구리, 망간, 아 연, 마그네슘, 셀레니움 등의 필수 미량 원소를 고르게 포함하여 있어 영양적으로 매우 우수한 식품이다.Maca (Lepidium meyenii) is a type of cruciferous vegetable that grows naturally in the Peruvian Andes at an altitude of 4,000 to 4,500 m. It is called by various names such as maca-maca, maino, and ayak willku. Maca is an edible and medicinal plant that is well known for its strong vitality and various useful physiological activities that survive in harsh natural environments, so much so that it is called the wild ginseng of Peru. The underground part of Maca, which is used as food, has already been proven safe through long-term consumption, and is widely used in Korea. Its use as a supplementary ingredient in food has been permitted by the Food and Drug Administration since 2005 (Kwon Dae-jung et al., 2009, Food Industry and Nutrition 14: 19-24). Maca root has a moisture content of over 80% and, based on dry weight, contains 8.87-11.6% crude protein, 1.09-2.2% crude fat, 4.9-5.0% ash, 54.6-60.0% carbohydrate, and 8.23-9.08% dietary fiber. It is known (Dini A et al., 1994. Food Chem 49: 347-349). In addition, it is a nutritionally excellent food as it contains fatty acids such as oleic acid, linoleic acid, and palmitic acid and essential trace elements such as iron, calcium, iodine, copper, manganese, zinc, magnesium, and selenium.
또한, 마카는 성욕을 촉진하는 p-methoxybenzyl isothiocyantes와 다량의 단백질을 포함하여, 성기능 회복효과가 잘 알려져 있으며, 성기능 개선효과(Gonzales GF. 외, 2004, J Endocrinol 180: 87~95), 정자수 증가에 미 치는 영향(Dording CM. 외, 2008, CNS Neurosci Ther 14: 182~191), 여성의 폐경 후 증후군 완화효과(Zhang Y. 외 2014, Indian J. Pharmacol. 46: 416~419), 운동능력 향상 및 항피로 효과(Yu L. 외 2004. Food Science 25: 164~166), 항산화 활성(Zhang & Zhang, 2014. Natural Product R&D, 26: 813~818; Valentova K 외, 2006. Cell Biol Toxicol 22: 91~99) 등이 보고되어 있으며, 최근에는 기억력 증진(이홍미 외, 2010, 한국식품영양학 회지 23: 485~491), 항우울증 효과, UV 에 대한 피부 보효효과(Campous D. 외, 2013, Ind Crop Prod 49: 747~754), 항바이러스 효과(Mendoza J. 외, 2014. Asian Pacific journal of tropical medicine v.7 suppl.1, S415~S420) 등이 알려지고 있다. 또한, 마카 지질 추출물로부터 macamides가 분리 보고(이승호 외, 2008, 한국 생물공학회지 23: 153~157)된 바 있으며, 이는 fatty acid amide hydrolase 저해활성이 우수하다고 알려져 있고(Wu H 등, 2013, Bioorg Med Chem. 21: 5188~5197), 이외에도, 마카는 류마티스 관절염, 호흡기질환 등의 증 상 완화 및 치료, 호르몬 분비 조절, 대사촉진 효과가 있는 것으로 알려져 있다(권윤숙 외, 2009, 한국식품영양 과학회지 38: 817~823). 최근에는 마카 및 마카 추출물을 이용한 가공식품 개발에도 연구가 진행되고 있으며, 대표적으로 마카 추출물을 이용한 음료(전인숙 외, 2011. 한국식품저장유통학회지, 18: 669~677), 요쿠르트(정 해정 외, 2010. 한국식생활문화학회지, 25: 334~341) 및 시럽제조(정해정 외, 2010. 한국식품저장유통학회지, 17: 236~242) 등의 보고가 있다.In addition, maca contains p-methoxybenzyl isothiocyantes and a large amount of proteins that promote sexual desire, and is well known to have a sexual function recovery effect, improving sexual function (Gonzales GF. et al., 2004, J Endocrinol 180: 87~95), and sperm count. Effect on increase (Dording CM. et al., 2008, CNS Neurosci Ther 14: 182~191), effect on alleviating postmenopausal syndrome in women (Zhang Y. et al. 2014, Indian J. Pharmacol. 46: 416~419), exercise Performance improvement and anti-fatigue effect (Yu L. et al. 2004. Food Science 25: 164~166), antioxidant activity (Zhang & Zhang, 2014. Natural Product R&D, 26: 813~818; Valentova K et al., 2006. Cell Biol Toxicol 22: 91-99), etc. have been reported, and recently, memory improvement (Hongmi Lee et al., 2010, Korean Journal of Food and Nutrition 23: 485-491), antidepressant effect, and skin strengthening effect against UV (Campous D. et al., 2013) , Ind Crop Prod 49: 747~754), and antiviral effects (Mendoza J. et al., 2014. Asian Pacific journal of tropical medicine v.7 suppl.1, S415~S420). In addition, it has been reported that macamides have been isolated from maca lipid extract (Seungho Lee et al., 2008, Journal of the Korean Society of Biological Engineering 23: 153-157), which is known to have excellent fatty acid amide hydrolase inhibitory activity (Wu H et al., 2013, Bioorg Med Chem. 21: 5188~5197), In addition, maca is known to be effective in relieving and treating symptoms of rheumatoid arthritis and respiratory diseases, regulating hormone secretion, and promoting metabolism (Kwon Yun-sook et al., 2009, Journal of the Korean Society of Food and Nutrition) 38: 817-823). Recently, research is also being conducted on the development of processed foods using maca and maca extract, representative examples include beverages using maca extract (Jeon In-sook et al., 2011. Korean Journal of Food Storage and Distribution, 18: 669~677) and yogurt (Jeong Hae-jeong et al., There are reports such as 2010. Journal of the Korean Society of Food Culture and Culture, 25: 334-341) and syrup manufacturing (Jeong Hae-jeong et al., 2010. Journal of the Korean Society of Food Storage and Distribution, 17: 236-242).
마카를 건강보조식품에 적용하는 기술들로는 "성기능개선에 효과를 갖는 건강보조식품의 제조방법"(한국 등록특허공보 제10-1251976호, 특허문헌 1), "성기능 개선을 위한 건강보조식품용 환 및 이의 제조방법"(한국 공개특허공보 제10-2022-0100441호, 특허문헌 2) 등 다수의 기술이 공개되어 있다.Technologies for applying maca to health supplements include “Method for manufacturing health supplements effective in improving sexual function” (Korean Patent Publication No. 10-1251976, Patent Document 1), “Plans for health supplements to improve sexual function” A number of technologies have been disclosed, such as “and its manufacturing method” (Korean Patent Publication No. 10-2022-0100441, Patent Document 2).
하지만 마카는 섬유질이 과도한 소화 작용을 하여 가스를 다량 생성하고, 복통, 설사를 유발하며, 이로 인해 탈수를 유발하고, 체내 칼륨 수치의 급격한 상승을 일으키는 문제점이 있으며, 이 밖에도 불면증, 호르몬 불균형, 갑상선, 알레르기 등의 부작용을 일으킨다는 보고가 있다.However, maca has the problem of excessive digestion of fiber, which produces a large amount of gas, causes abdominal pain and diarrhea, which causes dehydration, and causes a rapid rise in potassium levels in the body. In addition, it can cause insomnia, hormonal imbalance, and thyroid problems. There are reports that it causes side effects such as allergies.
마카 외에도 혈행 개선과 성기능 개선을 목적으로 사용되는 여러 천연 원료들의 경우 대체적으로 복통과 설사 유발의 부작용을 일으킬 수 있어 그 양의 조절은 물론, 다른 원료와의 배합에 주의를 가져야 한다.In addition to maca, many natural ingredients used for the purpose of improving blood circulation and sexual function can generally cause side effects such as abdominal pain and diarrhea, so care must be taken not only in controlling the amount but also in mixing with other ingredients.
특히, 이러한 원료들은 전체적으로 열이 많기 때문에 평상시 열이 많은 사람들의 경우 복용량과 복용 회수에도 신경을 써야 한다.In particular, since these raw materials generally produce a lot of heat, people who usually have a lot of fever should pay attention to the dosage and number of times they are taken.
이처럼 천연원료를 기반으로 한 혈행 개선이나 성기능 개선을 목적으로 하는 건강보조식품을 제공함에 있어서 복통, 설사 등의 명현현상 혹은 부작용의 문제가 있는 바, 이의 개선이 필요한 실정이라 하겠다.In this way, in providing health supplements based on natural ingredients for the purpose of improving blood circulation or sexual function, there is a problem of side effects or side effects such as abdominal pain and diarrhea, so improvement is necessary.
또한, 통상적으로 평상시 휴대하고 다니면서 간편하게 취식할 수 있도록 환 형태로 제공되는데, 이러한 환 형태로 제공되는 제품의 경우 입에 삼긴 다음 체내에서 물에 의해 분해되어 흡수되기까지 충분한 시간을 거치지 못하여 유용한 성분이 체외로 배출되는 경우가 많다.In addition, they are usually provided in the form of pills so that they can be easily taken while being carried around on a daily basis. However, in the case of products provided in the form of pills, it does not take enough time for them to be broken down by water and absorbed in the body after being swallowed, so the useful ingredients are lost. It is often excreted outside the body.
또, 물 없이 취식하기 위해서는 입에 넣고 씹어야 하는데 씹히는 맛이 쓸 경우 취식에 거부감이 발생하기도 한다.Also, in order to eat without water, you have to put it in your mouth and chew it, but if the chewy taste is bitter, you may be reluctant to eat.
본 발명의 마카, 누에 등을 이용한 건강보조식품용 환의 제조 방법은 상기와 같은 종래 기술에서 발생하는 문제점을 해소하기 위한 것으로, 혈행 개선 및 성기능 개선에 효과가 있는 것으로 알려진 마카 및 누에번데기를 주 원료로 하여 환 형태로 제조하되, 물 없이 씹어서 취식할 때 맛과 향에 대한 거부감이 적고 체내 흡수가 원할히 이루어질 수 있게 하려는 것이다.The method of manufacturing pills for health supplements using maca, silkworm, etc. of the present invention is intended to solve the problems arising from the above-described prior art, and uses maca and silkworm pupae, which are known to be effective in improving blood circulation and sexual function, as the main raw materials. It is manufactured in the form of a pill, and when chewed without water, it is intended to reduce rejection of the taste and aroma and ensure smooth absorption in the body.
더하여, 산수유, 참당귀, 오미자, 계피를 적절히 첨가하여 맛과 향에 대한 거부감을 최소화하려는 것이다.In addition, cornelian cherry, angelica root, Schisandra chinensis, and cinnamon are added appropriately to minimize aversion to taste and aroma.
또한, 산수유, 참당귀, 오미자, 계파를 습윤가열과 가열건조를 각각 온도와 시간을 달리하여 한정하여 진행함으로써 복통, 설사 등의 부작용을 최소화할 수 있게 하려는 것이다.In addition, the purpose is to minimize side effects such as abdominal pain and diarrhea by limitedly performing wet heating and heat drying of Cornus officinalis, angelica root, Schisandra chinensis, and cinnamon at different temperatures and times.
본 발명의 건강보조식품용 환의 제조 방법은, 오미자가 적재된 제1망상판, 산수유가 적재된 제2망상판, 참당귀가 적재된 제3망상판, 계피가 적재된 제4망상판, 좀돌팥의 잎이 적재된 제5망상판을 준비하고, 온장고의 내부에 하부에서 상부로 제5망상판, 제1망상판, 제2망상판, 제3망상판, 제4망상판의 순서로 서로 이격되게 배치하는 배치단계와; 상기 온장고 내부 온도를 75 ~ 80℃의 상태로 유지하면서 온장고 하부로 수분을 공급하면서 3 ~ 4시간 유지하여 습윤가열하는 1차가열단계와; 상기 온장고 내부의 수분 공급을 중지한 채 온장고 내부 온도를 35 ~ 40℃의 온도로 6 ~ 8 시간 유지하여 가열건조하는 2차가열단계; 상기 온장고 내부 온도를 ℃의 상태로 유지하면서 온장고 하부로 수분을 공급하면서 12 ~ 18시간 유지하여 습윤가열하는 3차가열단계와; 상기 온장고 내부의 수분 공급을 중지한 채 온장고 내부 온도를 40 ~ 45℃의 온도로 6 ~ 12시간 유지하여 가열건조하는 4차가열단계와; 4차가열건조가 끝난 후의 오미자, 산수유, 참당귀, 계피를 각각 분쇄하는 분쇄단계와; 마카농축액 분말, 숫누에번데기 분말, 폴리코사놀 분말, L-아르지닌을 준비한 후, 상기 분쇄단계에서 분쇄 처리된 원료와 혼합하여 혼합물을 제조하되, 마카농축액 분말 20 ~ 30 중량%와, 숫누에번데기 분말 36 ~ 39 중량%와, 폴리코사놀 분말 10 ~ 11 중량%와, L-아르지닌 6 ~7 중량%와, 산수유 6 ~7 중량%와, 참당귀 5 ~ 6 중량%와, 오미자 5 ~ 7중량%와, 계피 2 ~ 3중량%가 되도록 혼합하는 혼합단계와; 상기 혼합물을 환 형태로 성형하는 성형단계;를 포함하여 구성된다.The method of manufacturing the pill for health supplement of the present invention includes the first reticulate plate loaded with Schisandra chinensis, the second reticulated plate loaded with Cornus officinalis, the third reticulated plate loaded with Angelica gigas, the fourth reticulated plate loaded with cinnamon, and the fourth reticulated plate loaded with cinnamon. Prepare the 5th mesh plate loaded with red bean leaves, and place them in the order of the 5th mesh plate, the 1st mesh plate, the 2nd mesh plate, the 3rd mesh plate, and the 4th mesh plate inside the heating cabinet from the bottom to the top. A placement step of spaced apart; A first heating step of moist heating by maintaining the internal temperature of the heating cabinet at 75 to 80°C for 3 to 4 hours while supplying moisture to the lower part of the heating cabinet; A secondary heating step of heating and drying the refrigerator by maintaining the internal temperature of the refrigerator at a temperature of 35 to 40°C for 6 to 8 hours while stopping the supply of moisture to the interior of the refrigerator; A third heating step of moist heating by maintaining the internal temperature of the heating cabinet at ℃ for 12 to 18 hours while supplying moisture to the lower part of the heating cabinet; A fourth heating step of heating and drying the refrigerator by maintaining the internal temperature of the refrigerator at a temperature of 40 to 45°C for 6 to 12 hours while stopping the supply of moisture to the interior of the refrigerator; A pulverizing step of pulverizing Schisandra chinensis, Cornus officinalis, angelica root, and cinnamon after the fourth heat drying process is completed; After preparing maca concentrate powder, male silkworm pupa powder, policosanol powder, and L-arginine, they are mixed with the raw materials pulverized in the grinding step to prepare a mixture, comprising 20 to 30% by weight of maca concentrate powder and male silkworm pupa powder. 36 to 39% by weight, 10 to 11% by weight of policosanol powder, 6 to 7% by weight of L-arginine, 6 to 7% by weight of Cornus officinalis, 5 to 6% by weight of Angelica gigas, and 5 to 7% by weight of Schisandra chinensis. A mixing step of mixing cinnamon to 2 to 3% by weight; It includes a molding step of molding the mixture into a ring shape.
삭제delete
삭제delete
삭제delete
삭제delete
삭제delete
삭제delete
본 발명에 의해, 혈행 개선 및 성기능 개선에 효과가 있는 것으로 알려진 마카 및 누에번데기를 주 원료로 하여 환 형태로 제조하되, 물 없이 씹어서 취식할 때 맛과 향에 대한 거부감이 적고 체내 흡수가 원할히 이루어질 수 있게 된다.According to the present invention, maca and silkworm pupae, which are known to be effective in improving blood circulation and sexual function, are used as main raw materials to manufacture them in the form of pills, but when chewed and consumed without water, there is little resistance to taste and aroma and the product is easily absorbed into the body. It can be accomplished.
더하여, 산수유, 참당귀, 오미자, 계피를 적절히 첨가하여 맛과 향에 대한 거부감이 최소화할 수 있게 된다.In addition, by appropriately adding Cornus officinalis, angelica root, Schisandra chinensis, and cinnamon, aversion to taste and aroma can be minimized.
또한, 산수유, 참당귀, 오미자, 계파를 습윤가열과 가열건조를 각각 온도와 시간을 달리하여 한정하여 진행함으로써 복통, 설사 등의 부작용이 최소화할 수 있게 된다.In addition, side effects such as abdominal pain and diarrhea can be minimized by limited wet heating and heat drying of Cornus officinalis, angelica root, Schisandra chinensis, and cinnamon at different temperatures and times.
도 1 내지 3은 실험예 1에 따른 시험성적서 발췌본
도 4는 실험예 2에 따른 그래프.
도 5는 실험예 3에 따른 그래프.
도 6 내지 7은 실험예 4에 따른 그래프.
도 8 내지 9는 실험예 5에 따른 그래프.
도 10 내지 11은 실험예 6에 따른 그래프.
도 12 내지 13은 실험예 7에 따른 그래프. Figures 1 to 3 are excerpts of test reports according to Experimental Example 1
Figure 4 is a graph according to Experimental Example 2.
Figure 5 is a graph according to Experimental Example 3.
6 to 7 are graphs according to Experimental Example 4.
8 to 9 are graphs according to Experimental Example 5.
10 to 11 are graphs according to Experimental Example 6.
12 to 13 are graphs according to Experimental Example 7.
이하, 본 발명의 마카, 누에 등을 이용한 건강보조식품용 환 및 제조 방법에 대해 상세히 설명하기로 한다.Hereinafter, the pills and manufacturing method for health supplements using maca, silkworm, etc. of the present invention will be described in detail.
본 발명의 건강보조식품용 환은 마카농축액 분말, 숫누에번데기 분말, 폴리코사놀 분말, L-아르지닌, 산수유, 참당귀, 오미자, 계피를 유효성분으로 한다.The pill for health supplement of the present invention contains maca concentrate powder, silkworm pupa powder, policosanol powder, L-arginine, Cornus officinalis, Angelica gigas, Schisandra chinensis, and cinnamon as active ingredients.
마카는 전술한 바와 같이 여러 우수한 효능을 갖고 있는 한편, 섬유질의 과도한 소화 작용에 따른 다량의 가스 생성으로 인한 복통 및 설사 유발, 그리고 이로 인한 탈수 현상을 일으키는 문제점도 보고되어 있다.As mentioned above, while Maca has many excellent effects, it has also been reported to cause abdominal pain and diarrhea due to the production of a large amount of gas due to excessive digestion of fiber, and to cause dehydration.
숫누에번데기는 단백질이 절반 이상이나 되고 단백질을 구성하는 필수아미노산이 골고루 들어 있으며, 티로신도 다량 함유되어 있어 영양가가 높다.Male silkworm pupa contains more than half of the protein, contains all the essential amino acids that make up protein, and also contains a large amount of tyrosine, making it highly nutritious.
하지만 이러한 숫누에번데기 역시 과다복용시 복통과 설사, 알레르기 등의 부작용이 있는 것으로 알려져 있다.However, these male silkworm pupae are also known to have side effects such as abdominal pain, diarrhea, and allergies when overdosed.
L-아르지닌(L-Arginine)은 조건부 필수 아미노산 중의 하나로 체내의 암모니아를 요소로 변환시킬 때 쓰이는 필수 요소이며, 혈관의 확장에 기여하는 일산화 질소를 체내에서 많들 때 기여하는 역할을 해 협심증이나 고혈압 증상의 치료에 사용되기도 한다. L-Arginine is one of the conditionally essential amino acids and is an essential element used when converting ammonia in the body into urea. It plays a role in contributing to angina pectoris and high blood pressure by contributing to nitric oxide, which contributes to the expansion of blood vessels, when there is too much nitric oxide in the body. It is also used to treat symptoms.
다만, L-아르지닌 복용시 다른 아미노산인 리신과의 균형이 무너질 경우 설사나 저혈압, 구내염 등의 부작용을 일으킨다고 알려져 있다.However, when taking L-arginine, it is known to cause side effects such as diarrhea, low blood pressure, and stomatitis if the balance with lysine, another amino acid, is disrupted.
폴리코사놀(policosanol)은 주로 사탕수수에서 얻을 수 있는 지방 알코올인데 양질의 콜레스테롤을 높여 혈압 조절 및 혈중 콜레스테롤 수치 개선에 도움을 주는 것으로 알려져 있다.Policosanol is a fatty alcohol mainly obtained from sugar cane and is known to help control blood pressure and improve blood cholesterol levels by increasing good cholesterol.
폴리코사놀 역시 위장 장애, 피부 발진 등의 부작용이 보고되고 있다.Policosanol has also been reported to have side effects such as gastrointestinal disorders and skin rashes.
상기한 주요 원료인 마카농축액 분말, 숫누에분데기 분말, 폴리코사놀 분말, L-아르지닌은 전술한 바와 같인 유용한 효과가 있음에도 불구하고 각각 소화계통의 부작용이 있는 것으로 알려져 있어 이들을 모두 포함하여 환을 제조할 경우 소화불량 및 설사 등의 문제점을 해소할 수 있어야 한다.Although the above-mentioned main raw materials such as maca concentrate powder, male silkworm powder, policosanol powder, and L-arginine have the beneficial effects described above, they are each known to have side effects on the digestive system, so pills are manufactured containing all of them. If done, it should be able to resolve problems such as indigestion and diarrhea.
뿐만 아니라, 마카 농축액 분말은 맛이 거의 향신료에 비교될 정도로 특유의 맛이 있어 호불호가 매우 강하며, 향 역시 특유의 비린 향이 있어 역시 취식 기호도에 상당히 안좋은 영향을 미친다. In addition, maca concentrate powder has a unique taste that is almost comparable to that of spices, so people like it and dislike it very much, and its scent also has a unique fishy smell, which has a significant negative effect on the preference for eating.
숫누에번데기 분말 역시 비린 냄새가 나기 때문에 취식 기호도에 상당히 않좋은 영향을 미친다.Raw silkworm pupa powder also has a fishy smell, so it has a significant negative effect on eating preferences.
본 발명에서 산수유, 참당귀, 오미자, 계피는 상기한 주요 원료로 인해 발생하는 맛과 향의 기호도 저하를 방지해주고, 취식 후의 복통, 설사를 방지하는 역할을 하게 된다.In the present invention, Cornus officinalis, angelica root, Schisandra chinensis, and cinnamon prevent the decline in taste and aroma preference caused by the above-mentioned main raw materials, and play a role in preventing stomachache and diarrhea after eating.
산수유는 층층나무과 산수유 나무의 열매로 맛은 시큼하고 떫은 맛이 나서 그 자체만으로 단독으로 다량 복용하기 어려운 원료이다. Cornus officinalis is the fruit of the Cornus officinalis tree of the dogwood family and has a sour and astringent taste, making it difficult to take in large quantities on its own.
산수유의 약리 성분으로는 코르닌, 모로니사이드, 로가닌, 타닌, 사포닌 등이 다량 포함되어 있어 근육 수축력을 높여 방광의 조절능력을 향상시키고, 혈관내피세포와 평활근의 이완을 촉진시킨다는 연구가 있다.Studies have shown that Cornus officinalis contains a large amount of pharmacological ingredients such as cornin, moroniside, loganin, tannin, and saponin, which improves bladder control by increasing muscle contraction and promotes relaxation of vascular endothelial cells and smooth muscles. there is.
산수유는 그 자체로 발기부전의 개선 효과가 보고되는 점도 있으나, 본 발명에서는 산수유가 소화를 촉진시키는 역할을 함에 포커스를 맞추어 상기 주요 원료에 대한 보조 원료로 사용하였다.Cornus officinalis itself has been reported to have an effect in improving erectile dysfunction, but in the present invention, Cornus officinalis was used as an auxiliary ingredient to the main ingredients, focusing on its role in promoting digestion.
참당귀는 미나리과에 속하는 다년생 식물로 원료는 뿌리를 사용한다.Angelica gigas is a perennial plant belonging to the Apiaceae family, and its roots are used as raw material.
참당귀의 주요 약리 성분으로는 데커신, 노다케닌, 쿠미린, 베타시토스테롤 등의 성분이 있다.The main pharmacological components of Angelica gigas include decusin, nodakenin, cumirin, and beta-sitosterol.
이러한 참당귀는 데커신이 혈액 순환에 영향을 미치는 점도 있지만 특유의 향을 갖는데, 그 자체로는 특이취가 매우 강해 선호도가 갈리나, 본 발명에서는 전술한 마카의 독특한 냄새를 줄여주는 역할도 하게 된다.Angelica gigas has a unique scent, although decusin affects blood circulation. The unique smell itself is very strong, so preferences vary, but in the present invention, it also serves to reduce the unique smell of the maca described above.
오미자는 목련과 오미자 나무의 열매로 단맛, 쓴맛, 신맛, 짠맛, 매운맛을 느낄 수 있어 오미자라고 불리는데, 오미자에는 시잔드린, 고미신, 사관산, 시트리산 등의 성분이 혈압 수치 조절 및 혈중 중성지방과 콜레스테롤 수치를 낮추어 혈류 개선에 도움을 주는 것으로 알려져 있다.Schisandra chinensis is the fruit of the magnolia and Schisandra chinensis trees. It is called Schisandra chinensis because it can taste sweet, bitter, sour, salty, and spicy. Schisandra chinensis contains ingredients such as cizandrin, gomisin, sargwan acid, and citric acid, which help regulate blood pressure levels and neutralize triglycerides in the blood. It is known to help improve blood flow by lowering cholesterol levels.
본 발명에서는 이러한 역할 외에도 마카 특유의 맛을 억제해주는 역할을 한다.In the present invention, in addition to this role, it also serves to suppress the unique taste of maca.
계피는 다량의 폴리페놀 성분이 함유되어 있는데, 이 성분은 혈액 순환을 원할히 해 주는 것으로 알려져 있다.Cinnamon contains a large amount of polyphenol, which is known to improve blood circulation.
본 발명에서는 이러한 역할 외에도 계피 특유의 냄새와 맛으로 마카의 특이미와 특이취를 제어해주는 역할을 하게 된다.In the present invention, in addition to this role, it also plays a role in controlling the unique taste and smell of maca with the unique smell and taste of cinnamon.
본 발명에서 상기 유효성분은 다양한 배합이 가능하나. 마카농축액 분말 20 ~ 30 중량%와, 숫누에번데기 분말 36 ~ 39 중량%와, 폴리코사놀 분말 10 ~ 11 중량%와, L-아르지닌 6 ~7 중량%와, 산수유 6 ~7 중량%와, 참당귀 5 ~ 6 중량%와, 오미자 5 ~ 7중량%와, 계피 2 ~ 3중량%로 이루어진 것이 바람직하다.In the present invention, the active ingredients can be combined in various ways. 20 to 30% by weight of maca concentrate powder, 36 to 39% by weight of male silkworm pupa powder, 10 to 11% by weight of policosanol powder, 6 to 7% by weight of L-arginine, 6 to 7% by weight of Cornus officinalis, and Cham. It is preferably composed of 5 to 6% by weight of angelica root, 5 to 7% by weight of Schisandra chinensis, and 2 to 3% by weight of cinnamon.
상기 배합에서 마카농축액 분말 및 숫누에번데기 분말 함량이 최저 함량 미만일 경우 혈행 개선 효과가 미비하며, 과량 포함될 경우 이미와 이취가 강해져 기호도가 떨어지게 된다.In the above combination, if the content of maca concentrate powder and male silkworm pupa powder is less than the minimum content, the effect of improving blood circulation is minimal, and if it is included in excessive amounts, the taste and off-flavor become stronger and the preference decreases.
더불어, 상기 산수유, 참당귀, 오미자, 계피 함량이 최저 함량 미만일 경우 마카농축액 분말 및 숫누에번데기 분말에서 발생하는 이미와 이취가 심해 기호도를 떨어뜨리며, 반대로 과량 포함될 경우 산수유, 참당귀, 오미자, 계피 자체가 갖고 있는 맛과 향이 느껴져 기호도를 떨어뜨릴 수 있다.In addition, if the content of Cornus officinalis, angelica root, Schisandra chinensis, and cinnamon is less than the minimum content, the taste and off-flavor generated from the maca concentrate powder and male silkworm pupa powder will be severe, reducing the palatability. Conversely, if it is included in excessive amounts, the content of Cornus officinalis, angelica root, Schisandra chinensis, and cinnamon will be strong. The taste and scent of the product itself can be felt, which can reduce preference.
이때, 산수유, 참당귀, 오미자, 계피는 그 자체로 맛과 향이 강하고, 생물의 경우 원료의 채취 시기, 채취 장소 등 환경에 따라 그 맛과 향이 제각각이어서 상기 마카농축액 분말 및 숫누에번데기 분말의 맛과 향을 억제하기 위한 배합 비율을 일률적으로 적용하기에 어려움이 있다.At this time, Cornus officinalis, angelica root, Schisandra chinensis, and cinnamon have a strong taste and scent in themselves, and in the case of living organisms, the taste and scent vary depending on the environment such as the time of collection of raw materials and the location of collection, so the taste of the maca concentrate powder and male silkworm pupa powder It is difficult to uniformly apply the mixing ratio to suppress overindulgence.
또한, 마카농축액 분말 및 숫누에번데기 분말 자체로 따뜻한 성질을 갖는데, 산수유, 참당귀, 오미자, 계피 역시 따뜻한 성질을 가져 평소 열이 많은 사람들로 하여금 복용시 열이 더해지는 문제점이 발생할 수 있다.In addition, maca concentrate powder and male silkworm pupa powder themselves have warm properties, and Cornus officinalis, angelica root, Schisandra chinensis, and cinnamon also have warm properties, so people who usually have a lot of fever may experience the problem of increased heat when taking them.
이에 산수유, 참당귀, 오미자, 계피를 가공 처리하여 마카농축액 분말 및 숫누에번데기 분말의 맛과 향을 억제하기 위한 배합 비율이 균일해지도록 하고, 따뜻한 성질을 조정할 수 있다.Accordingly, Cornus officinalis, angelica root, Schisandra chinensis, and cinnamon are processed to ensure a uniform mixing ratio to suppress the taste and scent of maca concentrate powder and male silkworm pupa powder, and to adjust the warm properties.
이를 위한 처리는 다음과 같이 진행될 수 있다.Processing for this may proceed as follows.
1) 1차가열단계1) First heating stage
오미자, 산수유, 참당귀, 계피를 75 ~ 80℃의 온도로 3 ~ 4시간 동안 습윤 상태로 가열한다.Heat Schisandra chinensis, Cornus officinalis, angelica root, and cinnamon in a wet state at a temperature of 75 to 80°C for 3 to 4 hours.
2) 2차가열단계2) Secondary heating stage
상기 1차가열단계가 끝난 원료를 35 ~ 40℃의 온도로 6 ~ 8 시간 동안 가열건조한다.The raw materials that have completed the first heating step are heated and dried at a temperature of 35 to 40°C for 6 to 8 hours.
3) 3차가열단계3) Third heating stage
상기 2차가열단계가 끝난 원료를 45 ~ 50℃의 온도로 12 ~ 18 시간 동안 습윤 상태로 가열한다.The raw materials that have completed the secondary heating step are heated in a wet state at a temperature of 45 to 50°C for 12 to 18 hours.
4) 4차가열단계4) 4th heating stage
상기 3차가열단계가 끝난 원료를 40 ~ 45℃의 온도로 6 ~ 12시간 동안 가열건조한다.The raw materials that have completed the third heating step are heated and dried at a temperature of 40 to 45°C for 6 to 12 hours.
5) 분쇄단계5) Grinding step
상기 4차가열단계가 끝난 후의 오미자, 산수유, 참당귀, 계피를 각각 분쇄한다.After the fourth heating step is completed, Schisandra chinensis, Cornus officinalis, angelica root, and cinnamon are respectively pulverized.
6) 혼합단계6) Mixing step
마카농축액 분말, 숫누에번데기 분말, 폴리코사놀 분말, L-아르지닌을 준비한 후, 상기 분쇄단계에서 분쇄 처리된 원료와 혼합하여 혼합물을 제조한다.After preparing maca concentrate powder, male silkworm pupa powder, policosanol powder, and L-arginine, they are mixed with the raw materials pulverized in the grinding step to prepare a mixture.
7) 성형단계7) Forming stage
상기 혼합물을 환 형태로 성형한다.The mixture is molded into a ring shape.
상기한 공정에서 따뜻한 성질을 보다 더 약하게 하고, 각 원료의 맛과 향이 일정해질 수 있도록 하기 위하여 좀돌팥의 잎을 활용할 수 있다.In the above process, the leaves of the Jomdol red bean can be used to further weaken the warm property and to ensure that the taste and aroma of each raw material is consistent.
구체적으로 1차가열단계를 진행하기 전에 오미자가 적재된 제1망상판, 산수유가 적재된 제2망상판, 참당귀가 적재된 제3망상판, 계피가 적재된 제4망상판, 좀돌팥의 잎이 적재된 제5망상판을 준비하고, 온장고의 내부에 하부에서 상부로 제5망상판, 제1망상판, 제2망상판, 제3망상판, 제4망상판의 순서로 서로 이격되게 배치하는 배치단계가 진행될 수 있다.Specifically, before proceeding with the first heating step, the first reticulated plate loaded with Schisandra chinensis, the second reticulated plate loaded with Cornus officinalis, the third reticulated plate loaded with angelica root, the fourth reticulated plate loaded with cinnamon, and the red bean paste plate. Prepare the 5th mesh plate loaded with leaves, and space them apart from each other in the order of the 5th mesh plate, 1st mesh plate, 2nd mesh plate, 3rd mesh plate, and 4th mesh plate from the bottom to the inside of the heating cabinet. The deployment stage may proceed.
또, 1차가열단계 및 3차가열단계는 온장고 하부로 수분을 공급하여 온장고 내부가 습윤 상태가 되도록 하여 진행될 수 있다.In addition, the first heating step and the third heating step can be performed by supplying moisture to the lower part of the heating cabinet so that the inside of the heating cabinet is in a wet state.
이 경우 온장고 하부로 유입되는 수분이 비교적 높은 온도의 온장고 내부에서 빠르게 기화되어 온장고 내부가 습윤 상태가 되고, 최하층의 좀돌팥 잎이 가장 먼저 따뜻한 습기와 접촉하여 분해된 수용성 성분 및 지용성 성분이 온장고 내부에서 상층으로 이동하면서 산수유, 오미자, 참당귀, 계피 등에 제공되어 이들이 갖고 있는 특유의 향을 억제시키고, 따뜻한 성질도 약하게 할 수 있다.In this case, the moisture flowing into the lower part of the heating cabinet is quickly evaporated inside the heating cabinet at a relatively high temperature, making the inside of the heating cabinet wet, and the red bean leaves in the lowest layer are the first to come in contact with the warm moisture, causing the decomposed water-soluble and oil-soluble components to be stored inside the heating cabinet. As it moves from the upper floors, it is provided to cornelian cherry, Schisandra chinensis, angelica root, cinnamon, etc., suppressing their unique scent and weakening their warm properties.
이하에서는 본 발명에 따른 실시예와, 실시예와 비교하기 위한 비교예에 대해 설명하기로 한다.Hereinafter, examples according to the present invention and comparative examples for comparison with the examples will be described.
<실시예 1 및 비교예 1 내지 8의 제조><Preparation of Example 1 and Comparative Examples 1 to 8>
아래 표 1에 나와 있는 바와 같이 원료를 준비하여 혼합한 다음 제환기에 공급하여 환 형태로 제조하였다.As shown in Table 1 below, the raw materials were prepared, mixed, and then supplied to a ventilation machine to prepare them in the form of a ring.
(g)Sum
(g)
<실험예 1> 식품안정성 측정<Experimental Example 1> Food stability measurement
실시예 1에 의해 제조된 환(샘플 아이디 : 천기천)에 대해서 미국 캘리포니아 주 환경 연구소에 잔류 농약 검사를 의뢰한 결과, 잔류 농약은 불검출로 측정되었다.The pill prepared in Example 1 (Sample ID: Cheon Gi-cheon) was requested to be tested for pesticide residues at the Environmental Research Institute of California, USA. As a result, pesticide residues were measured as non-detectable.
이와 관련한 시험성정서 일부를 도 1, 2에 나타내었다.Some test reports related to this are shown in Figures 1 and 2.
더불어, 영양 성분 분석 후 1회 제공(100g) 당 기준 제공 함량을 도 3에 나타내었다.In addition, the standard serving content per serving (100g) after analysis of nutritional components is shown in Figure 3.
<실험예 2> 관능실험 1<Experimental Example 2> Sensory experiment 1
상기 실시예 1 및 비교예 1 내지 4의 환에 대하여 비린내, 풀내, 특이취에 대해 관능검사를 실시하여 비교하였다.The rings of Example 1 and Comparative Examples 1 to 4 were compared by performing sensory tests for fishy smell, grassy smell, and unusual odor.
관능검사는 9점 평점법을 이용하여 평가하였으며, 연령과 성별을 고려하여 30대 ~ 70내 성인 남녀를 각각 연령대별로 10명씩 총 40명을 선발하여 진행하였다.The sensory test was evaluated using a 9-point rating method, and considering age and gender, a total of 40 adult men and women in their 30s to 70s, 10 for each age group, were selected and conducted.
실험결과는 아래 표 2 및 도 4에 도시하였다.The experimental results are shown in Table 2 and Figure 4 below.
* 관능검사 수치(9: 아주 심함, 5 : 보통임, 0 : 아주 적음)* Sensory test values (9: very severe, 5: moderate, 0: very small)
상기 표 2 및 도 4의 결과로 볼 때, 실시예 1의 환은 비린내, 풀내, 특이취가 적은 반면, 비교예들은 비린내, 풀내, 특이취가 심한 것을 알 수 있다.From the results of Table 2 and Figure 4, it can be seen that the pills of Example 1 had a small fishy, grassy, and unusual odor, while the comparative examples had a strong fishy, grassy, and unique odor.
<실험예 3> 관능실험 2<Experimental Example 3> Sensory experiment 2
상기 실시예 1 및 비교예 1 내지 4의 환에 대하여 쓴맛, 신맛, 느끼한 맛, 특이미에 대해 관능검사를 실시하여 비교하였다.The pills of Example 1 and Comparative Examples 1 to 4 were compared by performing sensory tests on bitterness, sourness, greasy taste, and specific taste.
관능검사는 9점 평점법을 이용하여 평가하였으며, 연령과 성별을 고려하여 30대 ~ 70내 성인 남녀를 각각 연령대별로 10명씩 총 40명을 선발하여 진행하였다.The sensory test was evaluated using a 9-point rating method, and considering age and gender, a total of 40 adult men and women in their 30s to 70s, 10 for each age group, were selected and conducted.
실험결과는 아래 표 2 및 도 4에 도시하였다.The experimental results are shown in Table 2 and Figure 4 below.
* 관능검사 수치(9: 아주 심함, 5 : 보통임, 0 : 아주 적음)* Sensory test values (9: very severe, 5: moderate, 0: very small)
상기 표 3 및 도 5의 결과로 볼 때, 실시예 1의 환은 쓴맛, 신맛, 느끼한 맛 및 특이미가 적은 반면, 비교예들은 쓴맛, 신맛, 느끼한 맛 및 특이미가 심한 것을 알 수 있다.From the results of Table 3 and Figure 5, it can be seen that the pills of Example 1 had less bitterness, sourness, greasy taste, and specific taste, while the comparative examples had severe bitterness, sourness, greasy taste, and specific taste.
<실시예 2 내지 16의 제조><Preparation of Examples 2 to 16>
실시예 1과 동일하게 제조하되, 배합 비율을 각기 달리 아래 표 4와 같이 하여 실시예 2 내지 16을 제조하였다.Examples 2 to 16 were prepared in the same manner as Example 1, but with different mixing ratios as shown in Table 4 below.
<실험예 4> 관능실험 3<Experimental Example 4> Sensory experiment 3
상기 실시예 1 내지 16의 환에 대하여 비린내, 풀내, 특이취에 대해 관능검사를 실시하여 비교하였다.The rings of Examples 1 to 16 were compared by performing sensory tests for fishy smell, grassy smell, and unusual odor.
단, 제조 직후 및 제조후 상온에서 10일 경과 후 두차례 측정하여 그 결과를 비교하여 나타내었다.However, it was measured twice immediately after manufacturing and after 10 days at room temperature after manufacturing, and the results were compared and presented.
관능검사는 9점 평점법을 이용하여 평가하였으며, 연령과 성별을 고려하여 30대 ~ 70내 성인 남녀를 각각 연령대별로 10명씩 총 40명을 선발하여 진행하였다.The sensory test was evaluated using a 9-point rating method, and considering age and gender, a total of 40 adult men and women in their 30s to 70s, 10 for each age group, were selected and conducted.
실험결과는 아래 표 5(제조 직후), 표 6(상온에서 10일 경과 후) 및 도 6, 7에 도시하였다.The experimental results are shown in Table 5 (immediately after manufacturing), Table 6 (after 10 days at room temperature), and Figures 6 and 7 below.
* 관능검사 수치(9: 아주 심함, 5 : 보통임, 0 : 아주 적음)* Sensory test values (9: very severe, 5: moderate, 0: very small)
상기 표 5, 6 및 도 6,7의 결과로 볼 때, 제조 직후의 경우 실시예 1,2와 나머지 실시예들의 실험 결과가 큰 차이가 없었으나, 상온에서 10일 노출 후 실시예 1,2의 경우 제조 직후와 향의 차이가 별로 없는 반면, 나머지 실시예들은 비린내, 풀내, 특이취가 큰 폭으로 증가하는 것으로 나타난 바, 실시예 1, 2의 배합비로 제조하는 것이 보다 바람직한 것을 알 수 있었다.Looking at the results in Tables 5 and 6 and Figures 6 and 7, there was no significant difference between the experimental results of Examples 1 and 2 and the remaining examples immediately after manufacturing, but after exposure for 10 days at room temperature, Examples 1 and 2 In the case of , there was little difference in scent immediately after production, whereas in the remaining examples, fishy odor, grassy odor, and unusual odor increased significantly, and it was found that it was more preferable to manufacture with the mixing ratio of Examples 1 and 2. .
<실험예 5> 관능실험 4<Experimental Example 5> Sensory experiment 4
상기 실시예 1 내지 16의 환에 대하여 쓴맛, 신맛, 느끼한 맛, 특이미에 대해 관능검사를 실시하여 비교하였다.The pills of Examples 1 to 16 were compared by performing sensory tests on bitterness, sourness, greasy taste, and specific taste.
단, 제조 직후 및 제조후 상온에서 10일 경과 후 두차례 측정하여 그 결과를 비교하여 나타내었다.However, it was measured twice immediately after manufacturing and after 10 days at room temperature after manufacturing, and the results were compared and presented.
관능검사는 9점 평점법을 이용하여 평가하였으며, 연령과 성별을 고려하여 30대 ~ 70내 성인 남녀를 각각 연령대별로 10명씩 총 40명을 선발하여 진행하였다.The sensory test was evaluated using a 9-point rating method, and considering age and gender, a total of 40 adult men and women in their 30s to 70s, 10 for each age group, were selected and conducted.
실험결과는 아래 표 7(제조 직후), 표 8(상온에서 10일 경과 후) 및 도 8, 9에 도시하였다.The experimental results are shown in Table 7 (immediately after manufacturing), Table 8 (after 10 days at room temperature), and Figures 8 and 9 below.
* 관능검사 수치(9: 아주 심함, 5 : 보통임, 0 : 아주 적음)* Sensory test values (9: very severe, 5: moderate, 0: very small)
상기 표 7, 8 및 도 8,9의 결과로 볼 때, 제조 직후의 경우 실시예 1,2와 나머지 실시예들의 실험 결과가 큰 차이가 없었으나, 상온에서 10일 노출 후 실시예 1,2의 경우 제조 직후와 맛의 차이가 별로 없는 반면, 나머지 실시예들은 쓴맛, 신맛, 느끼한 맛, 특이미가 큰 폭으로 증가하는 것으로 나타난 바, 실시예 1, 2의 배합비로 제조하는 것이 보다 바람직한 것을 알 수 있었다.Looking at the results in Tables 7 and 8 and Figures 8 and 9, there was no significant difference between the experimental results of Examples 1 and 2 and the remaining examples immediately after manufacturing, but after exposure for 10 days at room temperature, Examples 1 and 2 In the case of , there was not much difference in taste immediately after production, while in the remaining examples, bitterness, sourness, greasy taste, and peculiar taste were shown to increase significantly. Therefore, it was found that it was more preferable to prepare with the mixing ratio of Examples 1 and 2. I was able to.
<실시예 17 내지 35의 제조><Preparation of Examples 17 to 35>
실시예 1과 동일한 배합을 취하되, 제조 공정을 다음과 같이 진행하였다.The same formulation as Example 1 was used, but the manufacturing process was carried out as follows.
우선, 제1망상판에 오미자를, 제2망상판에 산수유를, 제3망상판에 참당귀를, 제4망상판에 계피를 적재한 다음, 온장고 내부에 아래에서 위로 제1망상판, 제2망상판, 제3망상판, 제4망상판의 순서로 서로 이격되게 배치하였다.First, place Schisandra chinensis on the first reticle plate, Cornus officinalis on the second reticle plate, angelica root on the third reticle plate, and cinnamon on the fourth reticle plate, and then place the first reticle plate, They were arranged spaced apart from each other in the following order: 2nd reticular plate, 3rd reticular plate, and 4th reticular plate.
그런 다음 1차가열, 2차가열, 3차가열, 4차가열의 순서로 아래 표 9와 같은 조건으로 설정하여 각각의 실시예를 진행하였다.Then, each example was conducted under the conditions shown in Table 9 below in the following order: first heating, second heating, third heating, and fourth heating.
이때, 1차가열과 3차가열은 온장고 하부로 수분을 공급하면서 진행하였다.At this time, the first heating and third heating were carried out while supplying moisture to the lower part of the refrigerator.
4차가열까지 끝난 후에는 오미자, 산수유, 참당귀, 계피를 각각 분쇄 처리하였으며, 실시예 1과 같은 배합비로 원료를 혼합하여 혼합물을 제조한 후, 제환기에서 환 모양으로 성형하였다.After the fourth heating was completed, Schisandra chinensis, Cornus officinalis, Angelica gigas, and cinnamon were each ground and processed, and the mixture was prepared by mixing the raw materials in the same mixing ratio as in Example 1, and then molded into a ring shape in a ventilation machine.
실시예 35는 제5망상판을 준비한 후, 좀돌팥의 잎을 적재한 다음 제1망상판의 하부에 배치하고, 실시예 18과 동일한 조건으로 진행하였다.Example 35 was conducted under the same conditions as Example 18 by preparing the fifth reticulate plate, loading the leaves of Jomdol red bean, and then placing them in the lower part of the first reticular plate.
(온도 : ℃, 시간 : H)(Temperature: ℃, Time: H)
<실험예 6> 관능실험 5<Experimental Example 6> Sensory experiment 5
상기 실시예 1 및 17 내지 35의 환에 대하여 비린내, 풀내, 특이취에 대해 관능검사를 실시하여 비교하였다.The rings of Examples 1 and 17 to 35 were compared by performing sensory tests for fishy smell, grassy smell, and unusual odor.
단, 제조 직후 및 제조후 상온에서 10일 경과 후 두차례 측정하여 그 결과를 비교하여 나타내었다.However, it was measured twice immediately after manufacturing and after 10 days at room temperature after manufacturing, and the results were compared and presented.
관능검사는 9점 평점법을 이용하여 평가하였으며, 연령과 성별을 고려하여 30대 ~ 70내 성인 남녀를 각각 연령대별로 10명씩 총 40명을 선발하여 진행하였다.The sensory test was evaluated using a 9-point rating method, and considering age and gender, a total of 40 adult men and women in their 30s to 70s, 10 for each age group, were selected and conducted.
실험결과는 아래 표 10(제조 직후), 표 11(상온에서 10일 경과 후) 및 도 10, 11에 도시하였다.The experimental results are shown in Table 10 (immediately after manufacturing), Table 11 (after 10 days at room temperature), and Figures 10 and 11 below.
* 관능검사 수치(9: 아주 심함, 5 : 보통임, 0 : 아주 적음)* Sensory test values (9: very severe, 5: moderate, 0: very small)
상기 표 10, 11 및 도 10, 11의 결과로 볼 때, 실시예 17 내지 35를 실시예 1과 비교할 때 실시예 18, 19, 35의 경우 실시예 1과 비교하여 비린내, 풀내 및 특이취가 확연히 더 줄어든 것을 확인할 수 있다.From the results of Tables 10 and 11 and Figures 10 and 11, when comparing Examples 17 to 35 with Example 1, Examples 18, 19, and 35 had a fishy, grassy, and unusual odor compared to Example 1. You can see that it has clearly decreased further.
또, 상온에서 10일 노출 후 이러한 차이가 더 커진 것을 확인할 수 있었다.Additionally, it was confirmed that this difference became larger after 10 days of exposure at room temperature.
<실험예 7> 관능실험 6<Experimental Example 7> Sensory experiment 6
상기 실시예 1 및 17 내지 35의 환에 대하여 쓴맛, 신맛, 느끼한 맛, 특이미에 대해 관능검사를 실시하여 비교하였다.The pills of Examples 1 and 17 to 35 were compared by performing sensory tests for bitterness, sourness, greasy taste, and specific taste.
단, 제조 직후 및 제조후 상온에서 10일 경과 후 두차례 측정하여 그 결과를 비교하여 나타내었다.However, it was measured twice immediately after manufacturing and after 10 days at room temperature after manufacturing, and the results were compared and presented.
관능검사는 9점 평점법을 이용하여 평가하였으며, 연령과 성별을 고려하여 30대 ~ 70내 성인 남녀를 각각 연령대별로 10명씩 총 40명을 선발하여 진행하였다.The sensory test was evaluated using a 9-point rating method, and considering age and gender, a total of 40 adult men and women in their 30s to 70s, 10 for each age group, were selected and conducted.
실험결과는 아래 표 12(제조 직후), 표 13(상온에서 10일 경과 후) 및 도 12, 13에 도시하였다.The experimental results are shown in Table 12 (immediately after manufacturing), Table 13 (after 10 days at room temperature), and Figures 12 and 13 below.
* 관능검사 수치(9: 아주 심함, 5 : 보통임, 0 : 아주 적음)* Sensory test values (9: very severe, 5: moderate, 0: very small)
상기 표 12, 13 및 도 12, 13의 결과로 볼 때, 실시예 17 내지 35를 실시예 1과 비교할 때 실시예 18, 19, 35의 경우 실시예 1과 비교하여 쓴맛, 신맛, 느끼한 맛, 특이미가 확연히 더 줄어든 것을 확인할 수 있다.From the results of Tables 12 and 13 and Figures 12 and 13, when comparing Examples 17 to 35 with Example 1, Examples 18, 19, and 35 had bitter, sour, and greasy taste compared to Example 1. You can see that the uniqueness has been noticeably reduced.
또, 상온에서 10일 노출 후 이러한 차이가 더 커진 것을 확인할 수 있었다.Additionally, it was confirmed that this difference became larger after 10 days of exposure at room temperature.
<실험예 8> 명현현상 실험<Experimental Example 8> Bright phenomenon experiment
40세 이상 70세 미만의 성인을 무작위로 95명을 선발하여 5명씩 한 조를 이루어 각각 실시예 1, 9, 11, 13, 15, 18, 20, 22, 24, 26, 28, 30, 32, 34, 35와, 비교예 1내지 4의 환을 물 없이 복용하도록 하였다.95 adults between 40 and 70 years of age were randomly selected and formed into groups of 5, respectively, in Examples 1, 9, 11, 13, 15, 18, 20, 22, 24, 26, 28, 30, and 32. , 34, 35, and Comparative Examples 1 to 4 were taken without water.
물의 섭취는 환 복용시만 금지시키고, 평상시와 같이 1리터 내지 1.5리터를 마시게 하였다.Intake of water was prohibited only when taking pills, and subjects were allowed to drink 1 liter to 1.5 liters as usual.
복용은 2일에 1회 꼴로 복용하게 하였으며, 복용 후 20일이 경과된 시점부터 각 그룹의 사람들의 명현현상 여부를 자가 점검토록 하였다.The drug was to be taken once every two days, and people in each group were asked to self-check whether or not they experienced a light phenomenon starting 20 days after taking the drug.
명현현상이 발생하는 경우 즉시 복용을 중단하도록 하였다.If the phenomenon of lightening occurs, take it immediately.
명현현상은 복통, 설사, 복부팽만감, 두통, 알러지로 분류하였다.The phenomenon was classified into abdominal pain, diarrhea, abdominal bloating, headache, and allergy.
실험 결과는 아래 표 4에 나타나 있다.The experimental results are shown in Table 4 below.
표 14를 보면 알 수 있듯이 실시예들은 명현 현상을 일으킨 수가 적은 반면, 비교예들의 경우 각 비교예별로 3명 이상 명현 현상이 발생하는 것으로 나타났다.As can be seen in Table 14, the examples showed a small number of people who experienced the manifesting phenomenon, while in the comparative examples, three or more people in each comparative example experienced the manifesting phenomenon.
Claims (5)
오미자가 적재된 제1망상판, 산수유가 적재된 제2망상판, 참당귀가 적재된 제3망상판, 계피가 적재된 제4망상판, 좀돌팥의 잎이 적재된 제5망상판을 준비하고, 온장고의 내부에 하부에서 상부로 제5망상판, 제1망상판, 제2망상판, 제3망상판, 제4망상판의 순서로 서로 이격되게 배치하는 배치단계와;
상기 온장고 내부 온도를 75 ~ 80℃의 상태로 유지하면서 온장고 하부로 수분을 공급하면서 3 ~ 4시간 유지하여 습윤가열하는 1차가열단계와;
상기 온장고 내부의 수분 공급을 중지한 채 온장고 내부 온도를 35 ~ 40℃의 온도로 6 ~ 8 시간 유지하여 가열건조하는 2차가열단계;
상기 온장고 내부 온도를 ℃의 상태로 유지하면서 온장고 하부로 수분을 공급하면서 12 ~ 18시간 유지하여 습윤가열하는 3차가열단계와;
상기 온장고 내부의 수분 공급을 중지한 채 온장고 내부 온도를 40 ~ 45℃의 온도로 6 ~ 12시간 유지하여 가열건조하는 4차가열단계와;
4차가열단계가 끝난 후의 오미자, 산수유, 참당귀, 계피를 각각 분쇄하는 분쇄단계와;
마카농축액 분말, 숫누에번데기 분말, 폴리코사놀 분말, L-아르지닌을 준비한 후, 상기 분쇄단계에서 분쇄 처리된 원료와 혼합하여 혼합물을 제조하되, 마카농축액 분말 20 ~ 30 중량%와, 숫누에번데기 분말 36 ~ 39 중량%와, 폴리코사놀 분말 10 ~ 11 중량%와, L-아르지닌 6 ~7 중량%와, 산수유 6 ~7 중량%와, 참당귀 5 ~ 6 중량%와, 오미자 5 ~ 7중량%와, 계피 2 ~ 3중량%가 되도록 혼합하는 혼합단계와;
상기 혼합물을 환 형태로 성형하는 성형단계;를 포함하여 구성된,
마카, 누에 등을 이용한 건강보조식품용 환의 제조 방법.In the method of manufacturing pills for health supplements,
Prepare the first reticulate plate loaded with Schisandra chinensis, the second reticulated plate loaded with Cornus officinalis, the third reticulated plate loaded with angelica root, the fourth reticulated plate loaded with cinnamon, and the fifth reticulated plate loaded with red bean leaves. And, an arrangement step of arranging the fifth mesh plate, the first mesh plate, the second mesh plate, the third mesh plate, and the fourth mesh plate to be spaced apart from each other from the bottom to the inside of the heating cabinet;
A first heating step of moist heating by maintaining the internal temperature of the heating cabinet at 75 to 80°C for 3 to 4 hours while supplying moisture to the lower part of the heating cabinet;
A secondary heating step of heating and drying the refrigerator by maintaining the internal temperature of the refrigerator at a temperature of 35 to 40°C for 6 to 8 hours while stopping the supply of moisture to the interior of the refrigerator;
A third heating step of moist heating by maintaining the internal temperature of the heating cabinet at ℃ for 12 to 18 hours while supplying moisture to the lower part of the heating cabinet;
A fourth heating step of heating and drying the refrigerator by maintaining the internal temperature of the refrigerator at a temperature of 40 to 45°C for 6 to 12 hours while stopping the supply of moisture to the interior of the refrigerator;
A grinding step of pulverizing Schisandra chinensis, Cornus officinalis, angelica root, and cinnamon after the fourth heating step is completed;
After preparing maca concentrate powder, male silkworm pupa powder, policosanol powder, and L-arginine, they are mixed with the raw materials pulverized in the grinding step to prepare a mixture, comprising 20 to 30% by weight of maca concentrate powder and male silkworm pupa powder. 36 to 39% by weight, 10 to 11% by weight of policosanol powder, 6 to 7% by weight of L-arginine, 6 to 7% by weight of Cornus officinalis, 5 to 6% by weight of Angelica gigas, and 5 to 7% by weight of Schisandra chinensis. A mixing step of mixing cinnamon to 2 to 3% by weight;
Constructed including; a molding step of molding the mixture into a ring shape,
Method of manufacturing pills for health supplements using maca, silkworm, etc.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020220096581A KR102587934B1 (en) | 2022-08-03 | 2022-08-03 | manufacturing method of attractive pill using Lepidium meyenii and silkworm |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020220096581A KR102587934B1 (en) | 2022-08-03 | 2022-08-03 | manufacturing method of attractive pill using Lepidium meyenii and silkworm |
Publications (1)
Publication Number | Publication Date |
---|---|
KR102587934B1 true KR102587934B1 (en) | 2023-10-13 |
Family
ID=88289707
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020220096581A KR102587934B1 (en) | 2022-08-03 | 2022-08-03 | manufacturing method of attractive pill using Lepidium meyenii and silkworm |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102587934B1 (en) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100692175B1 (en) * | 2005-03-25 | 2007-03-12 | 손병국 | Health functional food having an energetic and sturdy action |
JP2009525755A (en) * | 2006-02-07 | 2009-07-16 | ユーエス・ニュートラシューティカルズ・エルエルシー・ディービーエイ・ヴァレンサ・インターナショナル | Dietary supplement composition for blood lipid health |
KR101219911B1 (en) * | 2012-08-16 | 2013-01-09 | 정기철 | Manufacturing method of health supplement food using turmeric and health supplement food thereof |
KR101251976B1 (en) | 2011-07-07 | 2013-04-08 | 주식회사 한국지네틱팜 | Method producing for healthy food |
KR20140074422A (en) * | 2012-12-07 | 2014-06-18 | 주식회사 대화약품 | Method for manufacturing functional pill product using silkworm |
KR20220100441A (en) | 2021-01-08 | 2022-07-15 | 김주봉 | Pills for health supplement food for improving sexual function and manufacturing method thereof |
-
2022
- 2022-08-03 KR KR1020220096581A patent/KR102587934B1/en active IP Right Grant
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100692175B1 (en) * | 2005-03-25 | 2007-03-12 | 손병국 | Health functional food having an energetic and sturdy action |
JP2009525755A (en) * | 2006-02-07 | 2009-07-16 | ユーエス・ニュートラシューティカルズ・エルエルシー・ディービーエイ・ヴァレンサ・インターナショナル | Dietary supplement composition for blood lipid health |
KR101251976B1 (en) | 2011-07-07 | 2013-04-08 | 주식회사 한국지네틱팜 | Method producing for healthy food |
KR101219911B1 (en) * | 2012-08-16 | 2013-01-09 | 정기철 | Manufacturing method of health supplement food using turmeric and health supplement food thereof |
KR20140074422A (en) * | 2012-12-07 | 2014-06-18 | 주식회사 대화약품 | Method for manufacturing functional pill product using silkworm |
KR20220100441A (en) | 2021-01-08 | 2022-07-15 | 김주봉 | Pills for health supplement food for improving sexual function and manufacturing method thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101820761B1 (en) | Composition for improving sleep disturbance and sleep inducing | |
Shubhashree et al. | Therapeutic and nutritional values of Narikelodaka (tender coconut water)-A review | |
KR100990075B1 (en) | Raw rice wine containing herb extract and manufacturing process of the same | |
CN111567661A (en) | Composite gel candy and preparation method thereof | |
CN105475584A (en) | Selenium-enriched health care chocolate | |
KR102587934B1 (en) | manufacturing method of attractive pill using Lepidium meyenii and silkworm | |
CN101422268A (en) | Anti-cancer fish soup | |
KR101764306B1 (en) | The method for manufacturing of tea | |
Rajamohan et al. | Nutrition and health aspects of coconut | |
RU2545947C1 (en) | Dry mixture for ice cream production | |
RU2750886C1 (en) | Functional product | |
KR20040101694A (en) | A food containing -renolenic acid for a climacteric woman | |
KR102470155B1 (en) | Oral composition for reducing body weight or body fat comprising Artemisia dracunculus and Taraxacum officinale | |
KR20190102493A (en) | A pill for functional food comprising Protaetia brevitarsis seulensis and manufacturing method therof | |
KR20180126691A (en) | Oriental pills for the prevention, improvement or treatment of arthritis and methods for producing the same | |
CN106418401A (en) | Functional nut composition and food composition containing functional nut composition and scented tea | |
KR101875896B1 (en) | Health supplement food comprising horse bone and coral, and manufacturing method for the same | |
RU2115336C1 (en) | Bioactive preparation "propolin" | |
KR20200105441A (en) | Sugar free chestnut spread and a method for producing the same | |
KR20050080501A (en) | A making method of health assistance food for high blood pressure, fatness, diabetes patients. | |
Sharma et al. | Development and quality evaluation of peda manufactured from admixture of flaxseed and sesame seed | |
CN109619517A (en) | A kind of ginkgo nut nutrient powder | |
CN109362924B (en) | Quercus liaotungensis leaf health tea and preparation method thereof | |
Pathak et al. | Nutritional analysis of cereal bars formulated using Morinda citrofolia and Bacopa monnieri | |
KR102349905B1 (en) | Dietary food composition consisting of pumpkin, bellflower and apple with excellent customer satisfaction |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GRNT | Written decision to grant |